Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, Inc. (NASDAQ: ATRC) announced its fourth quarter and full year 2022 financial results will be released on February 21, 2023. An audio webcast and investor meetings are scheduled for the same date and also on February 14, 2023, at the BTIG MedTech Conference in Snowbird, Utah. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, with FDA-approved technologies such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System. These advancements cater to over 37 million Afib patients globally, cementing AtriCure's position in the medtech industry.
AtriCure, Inc. (Nasdaq: ATRC) announced preliminary financial results for Q4 2022 and provided 2023 guidance. Q4 revenue is expected at $88.0 million, a 20% increase from Q4 2021. Full year 2022 revenue reached $330.4 million, also reflecting 20% growth. Adjusted EBITDA is projected at a $4 million loss, while adjusted loss per share is estimated between $1.10 and $1.12. For 2023, revenue guidance is set at $380 million to $387 million, indicating a 15%-17% growth.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 am PST. The presentation can be accessed through the company’s Investors webpage. AtriCure is renowned for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® devices, which are used worldwide for the management of Afib, affecting over 37 million people globally.
AtriCure, Inc. (NASDAQ: ATRC) has announced its participation in the 34th Annual Piper Sandler Healthcare Conference. The company is set to present on November 30, 2022, at 9:30 a.m. Eastern Time. A live audio webcast can be accessed via the Investors section on AtriCure's website. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, providing innovative technologies including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices for left atrial appendage management.
AtriCure, Inc. (Nasdaq: ATRC) reported third quarter 2022 revenue of $83.2 million, an 18.1% increase from the previous year. U.S. revenue rose to $69.8 million, up 21.3%, driven by strong sales of the cryoSPHERE® probe and AtriClip® Flex·V® device. International revenue grew by 4.2% to $13.4 million. However, the company posted a loss from operations of $10.7 million, and adjusted EBITDA was negative at $0.7 million. Full-year guidance predicts revenue between $328 million and $333 million with an adjusted loss per share of $1.10 to $1.12.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in major investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 11:30 a.m. ET, with a live audio webcast available on their website. Additionally, they will host investor meetings at the Canaccord Genuity Medtech Forum on November 17, 2022. AtriCure provides innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® for Afib treatment, affecting over 37 million people worldwide.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced it will release its third quarter 2022 financial results on November 1, 2022, at 4:30 p.m. Eastern Time. The company invites investors to join an audio webcast to discuss the results, accessible on their corporate website. AtriCure is known for its innovative technologies, such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, which are widely used for Afib treatment and related conditions.
AtriCure, Inc. (NASDAQ: ATRC) announced an investor education webcast scheduled for September 28, 2022, at 2:00 p.m. ET, focusing on Hybrid AF Therapy. The webcast will feature insights from management and leading experts, alongside an interactive Q&A session. Interested participants can register on the company’s website. AtriCure is recognized for its innovative solutions addressing atrial fibrillation (Afib), with products such as the Isolator® Synergy™ Ablation System and AtriClip® LAA Exclusion System. These technologies cater to a market affecting over 33 million people globally.
AtriCure, Inc. (NASDAQ: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 1:30 p.m. Eastern Time. The event will be accessible via a live audio webcast on the company’s website. AtriCure specializes in innovative technologies for Afib treatment, with over 33 million people affected worldwide. Its FDA-approved Isolator® Synergy™ Ablation System leads the market in persistent Afib treatment.
AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter of 2022 with revenues reaching $84.5 million, a growth of 18.4% compared to the previous year. U.S. sales rose by 18.6% to $71.3 million, driven by significant demand for products like the cryoSPHERE® probe and AtriClip® devices. However, the company recorded a loss from operations of $13.7 million with an adjusted EBITDA loss of $3.2 million. For 2022, AtriCure anticipates revenues between $323 million and $333 million, reflecting 18% to 21% growth over 2021.